Company / R&D per Share
ResMed R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.26
FY2025
5-year range
$1.55 / $2.26
FY2021-FY2025
Trend
+7.8%
vs FY2024
Sector context
#40 of 103
Health Care
What the data says
At $2.26, ResMed's r&d per share ranks #40 of 103 in the Health Care sector. R&D per Share has increased for 9 consecutive years, from $0.84 in FY2016 to $2.26 in FY2025.
Based on SEC 10-K filings.
2.26 in FY2025 with a 5-year CAGR of +9.9%.
Improved from $1.96 to $2.26 over the past 2 years.
Health Care sector context is included.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +9.0%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Sector benchmark
#40 of 103 in Health CareTop 39% of 103This company $2.26 Sector average $2.13
▼
+5.8% above sector average
Key checks
Key Insights
- ResMed's r&d per share has grown for 9 consecutive years.
- In FY2025, r&d per share increased 7.8% year-over-year.
- Ranks #40 out of 103 companies in the Health Care sector.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 3.25 (safe zone, above 2.9 threshold)
- Strong profit margin: 27.2%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.26 | +7.8% |
| FY2024 | $2.09 | +6.4% |
| FY2023 | $1.96 | +12.8% |
| FY2022 | $1.74 | +12.0% |
| FY2021 | $1.55 | +10.6% |
| FY2020 | $1.41 | +11.0% |
| FY2019 | $1.27 | +16.0% |
| FY2018 | $1.09 | +6.3% |
| FY2017 | $1.03 | +21.6% |
| FY2016 | $0.84 | +3.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026